HOME ·

R&D Progress

CMS (00867.HK): China NDA Approval for Ruxolitinib Phosphate Cream in Atopic Dermatitis Adds a Second Indication
Tags：
CMS00867.HKR&D Progress
2026-09-03
CMS (00867.HK): Opzelura-Counterpart Baicor (Ruxolitinib Cream) Approved for Atopic Dermatitis in China
Tags：
CMS00867.HKR&D Progress
2026-09-03
AKESO (09926.HK): HARMONi-2 interim analysis of ivonescimab meets key secondary OS endpoint with statistical significance and clinical benefit
Tags：
AKESO09926.HKR&D Progress
2026-09-03
CUTIA-B (02487.HK): BLA for CU-20101 botulinum toxin type A for injection accepted by NMPA
Tags：
CUTIA-B02487.HKR&D ProgressNew Drug Marketing Application
2026-09-03
OCUMENSION-B (01477.HK): Phase III Trial of Dry Eye Drug OT-211 Completes Enrollment of 398 Patients in China
Tags：
OCUMENSION-B01477.HKR&D Progress
2026-09-02
HAIXI PHARMA (02637.HK): Oral Retinal Disease Drug HX9428 Files Phase IIa IND for Diabetic Macular Edema; Phase I Data in nAMD Disclosed
Tags：
HAIXI PHARMA02637.HKR&D Progress
2026-09-02
HANSOH PHARMA (03692.HK): NDA for HS-20093 in Small Cell Lung Cancer Accepted by NMPA
Tags：
HANSOH PHARMA03692.HKR&D Progress
2026-09-02
CSPC PHARMA (01093.HK): ADC candidate SYS6010 receives another Breakthrough Therapy designation in China for recurrent or metastatic head and neck squamous cell carcinoma
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-09-01
CSPC PHARMA (01093.HK): Phase I clinical trial of SYH2056 tablets for major depressive disorder officially initiated in China
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-09-01
CUMENSION-B (01477.HK): First Patient Dosed in Phase III Clinical Trial of OT-202 for Dry Eye Disease
Tags：
CUMENSION-B01477.HKR&D Progress
2026-08-31
SHANDONG XINHUA (00719.HK): Azithromycin Tablets Pass Generic Drug Consistency Evaluation
Tags：
SHANDONG XINHUA00719.HKR&D Progress
2026-08-31
HUTCHMED (00013.HK): ATLED (Fanregratinib) Approved by NMPA for FGFR2 Fusion Cholangiocarcinoma
Tags：
HUTCHMED00013.HKR&D Progress
2026-08-28
CANSINOBIO (06185.HK): Latest progress of mRNA technology platform, subsidiary signs co-development agreement for personalized therapeutic tumor vaccines
Tags：
CANSINOBIO06185.HKR&D Progress
2026-08-26
CSPC PHARMA (01093.HK): SYS6090 granted FDA Fast Track designation for MSS/pMMR metastatic colorectal cancer
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-08-26
CSPC PHARMA (01093.HK): SYS6010 meets primary endpoint in Phase III study for EGFR-mutant NSCLC after EGFR TKI failure
Tags：
CSPC PHARMA01093.HKR&D ProgressClinical Trial
2026-08-26
CSPC PHARMA (01093.HK): Recombinant respiratory syncytial virus vaccine SYS6057 approved for clinical trials in the US
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-08-25
IMMUNEONCO-B (01541.HK): First patient dosed in IMC-003 PAH trial, SAD and MAD dose cohorts fully enrolled
Tags：
IMMUNEONCO-B01541.HKR&D Progress
2026-08-25
CF PHARMTECH (02652.HK): ICF001 expands indications after implied approval from NMPA, covering four indications including pulmonary fibrosis
Tags：
CF PHARMTECH02652.HKR&D Progress
2026-08-24
BAIYUNSHAN PH (00874.HK): Subsidiary's Norepinephrine Bitartrate Injection Passes Generic Drug Consistency Evaluation
Tags：
BAIYUNSHAN PH00874.HKR&D Progress
2026-08-24
SHANDONG XINHUA (00719.HK): Obtains Drug Registration Certificate for Dapagliflozin Tablets
Tags：
SHANDONG XINHUA00719.HKR&D Progress
2026-08-21
Previous12 34